The abstract is read at the publisher; the summary is JClub's.
Neoadjuvant botensilimab plus balstilimab produced major pathologic responses in resectable non-metastatic colorectal cancer, achieving 41% (95% CI, 21%-64%) in pMMR and 100% (95% CI, 40%-100%) in dMMR.
- Why it matters: Effective immunotherapy for mismatch repair proficient colorectal cancer remains limited, and neoadjuvant strategies could reveal whether immune activation can remodel tumors without delaying surgery.
- What they did: In the NEST phase 2 trial, adults with non-metastatic CRC received botensilimab plus balstilimab before surgical resection; cohorts used BOT 75 mg d1 with BAL 240 mg d1, 15, plus additional BAL doses in cohorts B/C.
- The result: Treatment was safe and did not delay planned surgery in any patient, and tumor microenvironment analyses in responders showed increased CD8+ T-cell density and proportion, reduced FOXP3+ Tregs, and greater immune cell-cell interaction.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.